Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Solid Tumors Equipment Supplied In Usa
175 equipment items found
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR036. INDICATION: Solid Tumor. PLATFORM: CAR-T. PRECLINICAL: Claudin 18.2. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR031. INDICATION: HCC. PLATFORM: CAR-T. PRECLINICAL: GPC3. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
by:LIXTE Biotechnology Holdings, Inc. based inPasadena, CALIFORNIA (USA)
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing toxicity. In addition, given at very low doses in animal models of cancer, LB-100 markedly increased the ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
Natural killer (NK) cells, as their name implies, play an important role in ridding the body of cancer and viruses. NK cells are emerging as an increasingly important cell type for therapeutic development. Solid tumors are particularly challenging to treat and CAR-T cells have largely underperformed in the solid tumor setting. ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Our RAS-F portfolio includes lead and back-up small molecules that suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS, and NRAS effector pathways. This potentially enables a differentiated, RAS-targeted strategy for inhibiting the MAPK, PI3K, and TOR pathways that are implicated in cancer cell proliferation, survival, and differentiation (see figure). RAS itself ...
Manufactured by:T-Knife GmbH based inBerlin, GERMANY
TK-8001 is a CD8 TCR-T specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1. MAGE-A1 is associated with hallmarks of aggressive cancers and poor clinical prognosis, and there is an emerging body of evidence indicating its involvement as a potential driver of tumorigenesis. MAGE-A1 represents an attractive therapeutic target given the high unmet need in MAGE-A1 expressing cancers, no ...
Manufactured by:LGC SeraCare based inMilford, MASSACHUSETTS (USA)
The Seraseq Tumor Mutation DNA Mix v2 (AF7) HC is a multiplexed mixture of actionable biosynthetic DNA targets precisely blended with a single, well-characterized genomic background. This product is produced under rigorous design control and manufacturing practices to an allelic frequency of 7%, and is offered in a high concentration (HC) format at 25 ng/µL. Designed to assess the overall ...
Manufactured by:LGC SeraCare based inMilford, MASSACHUSETTS (USA)
Whole transcriptome RNA sequencing allows for the analysis of fusion genes with potential clinical utility that currently cannot be detected using the limited genomic coverage of targeted NGS panels. Additionally, some clinical cancer testing labs are evaluating whole transcriptome panels for improved diagnostic yields and clinical utilization for NGS-based tumor profiling test reimbursements. ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
FOTIVDA (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.1,2 AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA in March 2021 for the treatment of adult patients ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
ERBB inhibitor for Solid Tumors PHASE ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
S6K, AKT, RSK inhibitor for Solid Tumors PHASE ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types. The MAGE- A4 antigen is among the most commonly expressed cancer-testis antigens. We are conducting various trials with the ADP-A2M4 SPEAR T-cell in various solid ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
The 806TCR is in IND-enabling studies. NY-ESO-1 has been demonstrated clinically as a suitable target for TCR therapies for multiple solid tumors. T-Cure is currently exploring partnerships in developing “off-the-shelf” approaches to utilize this all natural but high affinity TCR in the clinic. T-Cure believes the 806TCR holds great promise as a ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
Tumors with specific FGFR aberrations: Solid tumors, Gastric cancer, Myelolymphoid neoplasms PHASE ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-801 is a structurally novel, oral, small molecule, reversible inhibitor of exportin-1 (XPO1), a nuclear transport protein implicated in both solid tumors and hematologic malignancies. SL-801 has demonstrated preclinical in vitro and in vivo antitumor activity against a wide array of solid and hematologic cancers. SL-801’s potential ...
Manufactured by:Context Therapeutics Inc. based inPhiladelphia, PENNSYLVANIA (USA)
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been challenging. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic target for many ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS172738 is a highly selective, reversible, ATP-competitive RET (Rearranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas. ...
Manufactured by:Theriva Biologics, Inc., formely known as ynthetic Biologics, Inc. based inRockville, MARYLAND (USA)
Solid tumors are complex organ-like structures consisting of cancer cells, vasculature, and tumor matrix. This dense extracellular matrix, also known as stroma, hampers the intratumoral accessibility of chemotherapy, antitumor immune cells, and oncolytic viruses. ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-400, our DeltEx Allo DRI, is a preclinical product candidate expanding the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” DeltEx DRI therapy. We aim to take the clinical results from the ongoing INB-200 and INB-100 clinical trials to provide the safety data to support an ...